Achieve Life Sciences, Inc. (ACHV) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Achieve Life Sciences reported revenue of $0. Net income was -$54.6M, or -$1.25 per diluted share. Operating activities generated -$49.5M of cash, leaving -$49.5M of free cash flow. At fiscal year end, Achieve Life Sciences held $41.8M in total assets against $20.3M in total liabilities, including $20.9M of cash and equivalents.
Open the full interactive Achieve Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Achieve Life Sciences Key Stats
| Share Price | $7.00 |
|---|---|
| Market Cap | $654.6M |
| 52-Week Range | $2.65 – $8.53 |
| Shares Outstanding | 93.5 million (basic, 2026 Q2) |
Achieve Life Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | — | — | $40.8M | $27.2M | $39.1M | $54.9M |
| Gross Profit | — | — | -$40.8M | -$27.2M | -$39.1M | -$54.9M |
| Operating Income | — | — | -$81.8M | -$54.7M | -$78.4M | -$55.1M |
| Pre-Tax Income | -$14.7M | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M |
| Net Income | -$14.7M | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M |
| Diluted EPS | -$5.42 | -$4.08 | -$4.00 | -$1.50 | -$1.24 | -$1.25 |
Achieve Life Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$14.4M | -$14.7M | -$10.2M | -$74.8M |
| Diluted EPS | -$0.28 | -$0.34 | -$0.19 | -$0.80 |
Achieve Life Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $35.9M | $43.0M | $24.8M | $15.5M | $12.8M | $20.9M |
| Current Assets | $37.0M | $44.6M | $27.3M | $17.0M | $36.5M | $39.9M |
| Total Assets | $40.3M | $47.5M | $30.0M | $19.4M | $38.6M | $41.8M |
| Current Liabilities | $2.9M | $4.5M | $21.6M | $20.8M | $6.7M | $9.1M |
| Total Long-Term Debt | — | $14.9M | — | — | $9.8M | $14.9M |
| Total Liabilities | $3.0M | $19.5M | $21.7M | $20.8M | $17.7M | $20.3M |
| Shareholders' Equity | $37.3M | $28.0M | $8.3M | -$1.4M | $20.9M | $21.5M |
Achieve Life Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$13.5M | -$29.4M | -$37.5M | -$24.5M | -$29.8M | -$49.5M |
| Cash From Investing | -$17,000 | — | — | -$21,000 | -$21.6M | $6.1M |
| Cash From Financing | $32.7M | $36.6M | $19.3M | $15.3M | $48.5M | $51.5M |
| Free Cash Flow | -$13.5M | — | — | -$24.5M | — | -$49.5M |
Figures from Achieve Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Achieve Life Sciences financials page for every line item.
Achieve Life Sciences Company Profile
| Ticker | ACHV |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Seattle, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000949858 |
Frequently Asked Questions
What was Achieve Life Sciences' revenue in fiscal 2025?
Achieve Life Sciences (ACHV) reported revenue of $0 for fiscal 2025.
What is Achieve Life Sciences' annual revenue history?
Achieve Life Sciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Achieve Life Sciences' net income in fiscal 2025?
Achieve Life Sciences reported net income of -$54.6M for fiscal 2025.
What was Achieve Life Sciences' earnings per share (EPS) in fiscal 2025?
Achieve Life Sciences' diluted EPS was -$1.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Achieve Life Sciences generate in fiscal 2025?
Achieve Life Sciences generated -$49.5M of free cash flow in fiscal 2025.
What was Achieve Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Achieve Life Sciences reported revenue of $0.
How much debt does Achieve Life Sciences have?
Achieve Life Sciences reported $14.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Achieve Life Sciences are outstanding?
Achieve Life Sciences reported a weighted average of 93.5 million basic shares outstanding in 2026 Q2.
What is Achieve Life Sciences' market cap?
Based on its latest closing price, Achieve Life Sciences (ACHV) has a market capitalization of about $654.6M.
When does Achieve Life Sciences' fiscal year end?
Achieve Life Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is Achieve Life Sciences headquartered?
Achieve Life Sciences lists its business address in Seattle, Washington in its SEC filings.
Achieve Life Sciences Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →